Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
389 participants
INTERVENTIONAL
2015-08-31
2018-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This technique is practiced at many hospitals, including the Heart Institute, and is not experimental. However no detailed national or international guidelines exist to assist physicians in performing cardioversion. Physicians use a variety of methods. Electrical cardioversion does not always restore normal rhythm. Adjusting the electrical energy dose, changing the electrode position and applying pressure to the electrodes may improve the success rate.
This study will look at the safety and efficacy of a protocol (step by step method) for electrical cardioversion. The protocol prescribes the electrical energy dose, the electrode position and the application of pressure to the electrodes the physician will use. The individual elements of the protocol (energy dose, electrode position and pressure application) are often used by physician in clinical practice but not necessarily in the step by step order.
The purpose of this study is to get all doctors to follow a standard protocol 'the Ottawa AF cardioversion protocol'. We think that using this protocol will improve overall cardioversion success rates. The results of this study may change usual practice in Canada and in other countries.
All supplies, equipment and medications used in the protocol cardioversion are approved by Health Canada.
We estimate that 389 participants from the University of Ottawa Heart Institute will be enrolled in the study over the next 2 years. The results will be compared with a group of previous patients.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Trial of Electrical Versus Pharmacological Cardioversion for RAFF in the ED
NCT01891058
Anteroposterior Versus Anterolateral Electrode Position for Electrical Cardioversion of Atrial Fibrillation
NCT05511389
Chemical vs Electrical Cardioversion for Emergency Department Patients With Acute Atrial Fibrillation
NCT01994070
Atrial Fibrillation Force Contact Ablation Study
NCT01693107
QOL Improvement After Cardioversion of Persistent AF (QOL-CAFRCT)
NCT05136131
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
All eligible and consenting patients will undergo elective electrical cardioversion for atrial fibrillation (AF) using the Ottawa AF protocol.The fact that the physician follows the protocol makes this experimental. Aside from following the protocol, subjects will receive standard care before, during and after the procedure. Outcomes of the procedure and clinical features know to affect cardioversion efficacy will be collected. These will be compared to a group of 500 previous patients who underwent elective electrical cardioversion for AF at the Heart Institute.
Methodology:
The Ottawa AF protocol prescribes the electrical energy dose, the electrode position and the application of pressure to the electrodes the physician will use. The individual elements of the protocol (energy dose, electrode position and pressure application) are often used by physician in clinical practice but not necessarily in the step by step order.
The Ottawa AF protocol prescribes the following:
* the starting energy dose (200 J) and electrode placement (anterior-posterior)
* the second electrode placement (anterior-lateral) if the first shock is not successful
* addition of pressure to electrodes if second shock is not successful
* step up of energy dose (360 J) along with pressure to electrodes if third shock is not successful
* optional further steps at physician's choice if fourth shock is not successful
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ottawa AF Cardioversion
elective electrical cardioversion for atrial fibrillation (AF) using the Ottawa AF protocol
Lifepak 20E Defibrillator, Licence No: 61944
Intervention will be carried out using Health Canada approved devices for electrical cardioversion, following the steps pre-specified in the Ottawa AF Protocol.
Ottawa AF Cardioversion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lifepak 20E Defibrillator, Licence No: 61944
Intervention will be carried out using Health Canada approved devices for electrical cardioversion, following the steps pre-specified in the Ottawa AF Protocol.
Ottawa AF Cardioversion
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* On continuous systemic oral anticoagulation for 28 days prior to the day of cardioversion or must have undergone a recent (\< 48 hrs) trans-esophageal echocardiogram prior to the day of cardioversion
* Able to provide informed consent
Exclusion Criteria
* Pregnancy
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
David Birnie
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
David Birnie
BSc (Hons), MB ChB, MRCP(UK), MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
David H Birnie, MD
Role: PRINCIPAL_INVESTIGATOR
Ottawa Heart Institute Research Corporation
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Ottawa Heart Institution
Ottawa, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Ramirez FD, Sadek MM, Boileau I, Cleland M, Nery PB, Nair GM, Redpath CJ, Green MS, Davis DR, Charron K, Henne J, Zakutney T, Beanlands RSB, Hibbert B, Wells GA, Birnie DH. Evaluation of a novel cardioversion intervention for atrial fibrillation: the Ottawa AF cardioversion protocol. Europace. 2019 May 1;21(5):708-715. doi: 10.1093/europace/euy285.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Form ID 2788
Identifier Type: OTHER
Identifier Source: secondary_id
20140415
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.